CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

22 2 2024 05:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

20 2 2024 05:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

24 1 2024 06:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

11 12 2023 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

14 11 2023 13:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

07 11 2023 06:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

19 10 2023 13:01:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

10 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces $23 Million Registered Direct Offering

29 9 2023 04:35:51 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

29 9 2023 04:30:58 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

06 9 2023 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 8 2023 13:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

02 8 2023 13:01:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

13 7 2023 05:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

30 6 2023 06:25:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

13 6 2023 06:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

07 6 2023 06:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 5 2023 13:01:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

04 5 2023 06:00:01 提供 Nasdaq GlobeNewswire

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

27 4 2023 06:00:01 提供 Nasdaq GlobeNewswire